Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radspherin in Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT06504147Phase 2Recruiting
- Sponsor
- Oncoinvent ASA
- Start
- Jun 2024
- Primary completion
- Feb 2028
- Modality
- Nanoparticles
- Countries
- 6
01
Overview
A Phase 2 trial of Radspherin in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), peritoneal carcinomatosis (PC), sponsored by Oncoinvent ASA. Started Jun 2024; status: recruiting.
02
Drugs
Radspherin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT06504147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06504147.